Benzinga · Oct 12, 2026
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $60 to $100.
TX
NASDAQ · TXG
10x Genomics, Inc.
Healthcare · Medical - Healthcare Information Services
$71.55
Up+$1.80 (+2.58%)
Updated Oct 24, 2026, 3:29 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.04B
- P/E ratio
- -27.21
- Dividend yield
- 0.00%
- 52-week range
- $12.08 – $102.81
- Volume
- 2.23M
- Avg. volume
- 2.84M
Price performance · TXG
TXG price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
TXG closed at $71.55 after 21 trading sessions, down 16.52% for the selected period.
- Last close
- $71.55
- Period change
- -16.52%
- Period low
- $69.75
- Period high
- $97.74
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $68.94 | $71.83 | $67.5201 | $71.55 | 2.23M |
| Oct 22, 2026 | $73.85 | $75.59 | $67.25 | $69.75 | 4.19M |
| Oct 21, 2026 | $70.92 | $77.55 | $70.10 | $75.59 | 3.12M |
| Oct 20, 2026 | $69.52 | $73.40 | $67.53 | $71.46 | 2.86M |
| Oct 19, 2026 | $71.48 | $72.48 | $68.50 | $69.89 | 2.53M |
| Oct 16, 2026 | $71.91 | $73.99 | $67.52 | $69.86 | 3.39M |
| Oct 15, 2026 | $69.346 | $73.74 | $68.57 | $72.39 | 4.32M |
| Oct 14, 2026 | $69.52 | $74.33 | $68.45 | $73.10 | 4.14M |
| Oct 13, 2026 | $74.50 | $74.55 | $71.25 | $71.79 | 4.04M |
| Oct 12, 2026 | $79.18 | $80.472 | $71.61 | $75.19 | 4.08M |
| Oct 9, 2026 | $78.60 | $85.12 | $78.52 | $80.65 | 3.69M |
| Oct 8, 2026 | $73.50 | $77.58 | $70.94 | $77.28 | 5.71M |
| Oct 7, 2026 | $77.52 | $82.7182 | $73.00 | $76.10 | 9.38M |
| Oct 6, 2026 | $100.33 | $102.81 | $79.90 | $80.66 | 9.06M |
| Oct 5, 2026 | $93.50 | $98.3199 | $92.26 | $97.74 | 3.1M |
| Oct 2, 2026 | $90.04 | $94.56 | $88.14 | $93.50 | 3.15M |
| Oct 1, 2026 | $89.30 | $92.9199 | $86.75 | $88.76 | 3.25M |
| Sep 30, 2026 | $92.30 | $95.16 | $90.23 | $90.36 | 3.75M |
| Sep 29, 2026 | $89.24 | $91.99 | $87.2901 | $90.04 | 3.45M |
| Sep 28, 2026 | $86.00 | $89.95 | $84.2735 | $88.50 | 3.37M |
| Sep 25, 2026 | $83.76 | $86.16 | $80.72 | $85.71 | 3.39M |
Latest TXG news
The latest Smart Investors Daily articles mentioning TXG.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TXG research
Overview
Company profile and research snapshot.
Company profile
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Morgan Stanley | Equal-Weight | — |
| Oct 13, 2026 | TD Cowen | Hold | — |
| Oct 12, 2026 | Canaccord Genuity | Buy | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 29, 2026 | Leerink Partners | Market Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 10, 2026
Why Are 10x Genomics (TXG) Shares Soaring Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.1% in the morning session after Bank of America raised its price target on the stock to $80 from $50 while keeping a Neutral rating.
Yahoo · Oct 9, 2026
Is 10x Genomics (TXG) Using Its Fred Hutch Oncology Alliance To Redefine Its Clinical Moat?
In early October 2026, 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to apply its Flex Apex, Xenium and, later, Atera platforms to biomarker discovery in advanced bladder cancer and residual disease detection in acute myeloid leukemia. This partnership is 10x Genomics’ first clinical research push into both solid tumors and blood cancers, potentially laying groundwork for how single cell and spatial readouts might one day inform oncologists’...
Yahoo · Oct 7, 2026
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
